# Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer

> **NCT05420220** · PHASE2 · RECRUITING · sponsor: **Jiangsu Alphamab Biopharmaceuticals Co., Ltd** · enrollment: 54 (estimated)

## Conditions studied

- Advanced Non-small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)
- **COMBINATION_PRODUCT:** Axitinib

## Key facts

- **NCT ID:** NCT05420220
- **Lead sponsor:** Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-15
- **Primary completion:** 2027-05-29
- **Final completion:** 2027-12-26
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2024-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05420220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05420220, "Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05420220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*